DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Hormonal Agents in Prostate and Breast Cancer: Takeaways and Best Practices for Strategy Planning

Hormonal therapy is a cornerstone of drug treatment for prostate cancer across all drug-treated populations (hormone-sensitive and castrate resistant settings) and is also widely used as a treatment for hormone-receptor positive breast cancer.

In prostate cancer, LHRH agonists and antagonists form the base of androgen depravation therapy and are commonly used in most stages of the disease, particularly for advanced prostate cancer. More recently, novel hormonal agents have been developed, such as Xtandi and Zytiga, which have iragengized the metastatic castrate-resistant prostate cancer (mCRPC) setting and captured worldwide sales of approximately $5 billion in 2017.

In breast cancer, aromatase inhibitors, and selective estrogen receptor modulators and downregulators are used throughout the neoadjuvant, adjuvant and recurrent/ metastatic settings, capturing over $2 billion in 2017 in the major-markets. Nonetheless, here we will mainly focus on prostate cancer hormonal agents, as in this indication there are more innovative late phase developments than in breast cancer.

In this eBook, DRG Oncology expert Carolina do Pazo shares her perspective on emerging therapies and trends shaping the future of the hormonal agents in prostate and breast cancer landscape.

Key topics covered include:

  • Current leading therapies
  • Emerging players, agents and trials to watch
  • Disease management and access issues
  • Perspectives from oncologist KOLs
  • Takeaways for biopharma strategists